Sinus dilation devices market is anticipated to grow at a significant CAGR of 9.0% during the forecast period (2024-2031). The market growth is attributed to the increase in demand for minimally invasive procedures, increasing awareness of balloon sinuplasty's benefits over other traditional methods, and an increasing prevalence of chronic sinusitis driving the market industry. According to the National Center for Biotechnology Information (NCBI), in August 2023, acute rhinosinusitis is a common diagnosis, accounting for approximately 30 million primary care visits and $11 billion in healthcare expenditure annually. It is also a common reason for antibiotic prescriptions in the US and throughout the globe.

Market Dynamics

Increasing Demand for Sinusitis Dilation Procedures

The increasing demand for sinus dilation procedures for the clinical management of sinusitis and the high prevalence of sinus problems among respiratory patients is contributing to industry growth. In particular, the market for dilation devices has been a hub for innovation, providing less invasive substitutes for conventional surgical methods. By improving accuracy and patient comfort, these devices—which range from balloon sinus dilatation systems to micro-endoscopic instruments—are revolutionizing sinus care. The increasing demand for minimally invasive therapies, which reflects patients' preferences for procedures that minimize trauma and speed recovery, is a major factor driving the market's rise.

Market Segmentation

• Based on the type, the market is segmented into sinus stents, balloon sinus dilation, endoscopic sinus surgery, and handheld instruments.

• Based on the end-users, the market is segmented into hospitals clinics, and ambulatory surgical centers.

Balloon Sinus Dilation is Projected to Hold the Largest Segment

Balloon sinus dilation is a safe, compact, adaptable, and efficient way to relieve sinusitis problems. The sinus dilation technique has a short recovery period and promotes patient comfort as it does not need tissue ablation. BSD treatments, subsequently, are transient, and patients might need to have additional procedures. Chronic rhinosinusitis (CRS), a persistent sinus inflammation, is treated with balloon sinuplasty. For instance, in February 2022, Medtronic plc, in healthcare technology, introduced the NuVent™ Eustachian tube dilation balloon, which has been cleared by the US FDA for the treatment of chronic, obstructive Eustachian Tube Dysfunction. The NuVent™ balloon enables surgeons to deliver treatment in an outpatient or office setting. It features a flexible balloon section that allows customized placement based on patient anatomy.

Hospitals and Clinics Segment to Hold a Considerable Market Share

Many surgeries are carried out in hospital settings. It is projected that the growing incidence of chronic sinusitis along with advantageous reimbursement standards would propel the segment's expansion. The capacity to perform intricate sinus procedures and the availability of medical equipment and infrastructure with modern amenities are expected to drive industry expansion. Hospitals are seen by the healthcare system as a strategic means of providing surgical services. Hospitals can perform minimally invasive operations, such as balloon sinus dilation. Furthermore, it is projected that the segment would develop its cost-effectiveness and superior reimbursement scenarios compared to ambulatory surgical centers.

Regional Outlook

Global sinus dilation devices market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America). 

Growing Demand for Sinus Dilation Devices in Asia-Pacific

• Increasing awareness about sinusitis treatment options and improving healthcare infrastructure are driving the demand for sinus dilation devices. According to the National Center for Biotechnology Information (NCBI), in December 2022, sinusitis was present among 52.5% of adult Indian patients who underwent a CT scan owing to nasal symptoms. The high prevalence of sinusitis in the region, along with the growing popularity and demand for minimally invasive surgeries owing to their advantages—such as smaller incisions, less scarring, high accuracy and decreased risk of complications, shorter hospital stays, and others—are anticipated to be major growth factors driving the sinus dilation devices market.

Global Sinus Dilation Devices Market Growth by Region 2024-2031

North America Holds Major Market Share

North America holds a significant share owing to several regional companies in the sinus dilation devices market, including Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corp., and others. The market growth is attributed to the increasing prevalence of chronic sinusitis, the introduction of new products, the presence of a strong healthcare infrastructure, and the increased prevalence of risk factors including smoking, a persistent cold, allergies, asthma, head injuries, and other variables all contribute to sinusitis in the region. According to the National Center for Biotechnology Information (NCBI), in March 2023, in the US there were up to 73 million restricted-activity days related to sinusitis and total direct medical costs of almost 2.4 billion, not including surgery or radiographic imaging. In addition, up to 14.7% of individuals surveyed in the National Health Interview Survey reported having had sinusitis the preceding year.

Market Players Outlook

*Note: Major Players Sorted in No Particular Order.

The major companies serving the sinus dilation devices market include Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corp., Smith & Nephew Healthcare, and Stryker Corp. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market. 

Recent Development

• In March 2024, Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) and allergy specialists, announced the US (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

The Report Covers

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the sinus dilation devices market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.